Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian L Wiens

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Circulation|May 29, 2008
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Nazzareno Galiè, Horst Olschewski, Ronald J Oudiz, et al.
Hepatology (Baltimore, Md.)|August 24, 2017
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L Friedman, Vlad Ratziu, Stephen A Harrison, et al.
The New England Journal of Medicine|August 31, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Truman J Milling, John W Eikelboom, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Circulation|May 29, 2008
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Nazzareno Galiè, Horst Olschewski, Ronald J Oudiz, et al.
Hepatology (Baltimore, Md.)|August 24, 2017
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L Friedman, Vlad Ratziu, Stephen A Harrison, et al.
The New England Journal of Medicine|August 31, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Truman J Milling, John W Eikelboom, et al.
Pageof 3